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Abstract
Latent transforming growth factor-beta-1 binding protein-2 (LTBP-2) belongs to the fibrillin-
LTBP superfamily of extracellular matrix proteins. LTBPs and fibrillins are involved in the
sequestration and storage of latent growth factors, particularly transforming growth factor β
(TGF-β), in tissues. Unlike other LTBPs, LTBP-2 does not covalently bind TGF-β, and its
molecular functions remain unclear. We are screening LTBP-2 for binding to other growth
factors and have found very strong saturable binding to fibroblast growth factor-2 (FGF-2)
(Kd = 1.1 nM). Using a series of recombinant LTBP-2 fragments a single binding site for
FGF-2 was identified in a central region of LTBP-2 consisting of six tandem epidermal
growth factor-like (EGF-like) motifs (EGFs 9–14). This region was also shown to contain a
heparin/heparan sulphate-binding site. FGF-2 stimulation of fibroblast proliferation was
completely negated by the addition of 5-fold molar excess of LTBP-2 to the assay. Confocal
microscopy showed strong co-localisation of LTBP-2 and FGF-2 in fibrotic keloid tissue sug-
gesting that the two proteins may interact in vivo. Overall the study indicates that LTBP-2 is
a potent inhibitor of FGF-2 that may influence FGF-2 bioactivity during wound repair particu-
larly in fibrotic tissues.
Introduction
Latent transforming growth factor-beta-1 binding protein-2 (LTBP-2) is a member of the
fibrillin-LTBP superfamily of extracellular matrix proteins. These proteins are all structurally
similar, consisting of a rod-like molecule of tandem EGF-like 6-cys repeats interspersed with
characteristic 8-cys motifs [1–5]. Fibrillins 1–3 form microfibrils which, together with a core of
elastin, are the main structural components of elastic fibers [2, 5]. LTBPs -1, 3, and 4, cova-
lently bind latent growth factor TGF-β and direct the growth factor to storage depots within
the extracellular matrix [1, 6]. Fibrillin microfibrils are considered to be a principal storage
location for these latent complexes and they act as critical regulators of TGF-β activation [7].
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Structurally, LTBP-2 is more similar to the other LTBPs than fibrillins, but like fibrillins, it
does not directly bind TGF-β [8, 9] and LTBP-2 function remains largely unclear. An early
study reporting that LTBP-2 null mice have embryonic lethality [10], has recently been contra-
dicted by Inoue et al. who presented a LTBP-2 null mouse with only a mild ocular phenotype
[11]. This result agrees more closely with LTBP-2 null humans who also have mild ocular phe-
notypes including glaucoma, megalocornea, ectopis lentis and microspherophakia [12–15]. It
has long been documented that LTBP-2 is associated with elastic fibers in developing elastic tis-
sues [8] and there is evidence that LTBP-2 may play a negative regulatory role in elastinogen-
esis, inhibiting tropoelastin interactions with fibulin-5 and heparan sulphate proteoglycans
[16]. In vitro studies have shown that LTBP-2 specifically binds to fibrillin-1 rather than fibril-
lin-2 and that LTBP-2 can compete with LTBP-1 for binding to the fibrillin-1 molecule, sug-
gesting that LTBP-2 may indirectly affect TGF-β bioavailability [17]. This idea is supported by
a recent study linking LTBP-2 gene mutations to a recessive form of Weill—Marchesani syn-
drome (WMS) [18] which is characterized by short stature, brachydactyly, thick fibrotic skin
and ectopia lentis (WMS, Online Mendelian Inheritance in Man # 608328). This finding clearly
links LTBP-2 to fibrillin biology as mutations in the fibrillin-1 gene also cause some presenta-
tions of WMS [19]. Fibrillin-1 gene mutations also cause Marfan Syndrome (MFS) (OMIM
number 154700) and many of the characteristics of WMS and MFS have been attributed to
aberrant TGF-β signaling [20]. However fibrillins and associated MAGP proteins have been
documented to bind many other growth factors in latent and/or active forms, including bone
morphogenic proteins (BMPs) 2, 4, 5, 7 and 10, and connective tissue growth factor [21–24].
Thus sequestration or release of these molecules may also influence microfibril modulation of
growth factor signaling and contribute to aberrant microfibril function in these genetic disor-
ders and other diseases.
Given the above evidence it seems clear that LTBP-2 also has some as yet unidentified role
in modulation of growth factor storage and activity. To investigate we have commenced
screening LTBP-2 with candidate growth factor binding partners. In this paper we report a
very strong interaction of LTBP-2 with fibroblast growth factor-2 (FGF-2). FGF-2 or basic FGF
is an important member of a family of cytokines now numbering over 20, that modulate cellu-
lar behaviour through activation of FGF receptors (FGFRs)[25]. FGF-2 promotes proliferation,
differentiation and migration in fibroblasts and a variety of other cell types [26] and has influ-
ence on a range of processes including angiogenesis, tissue remodeling, wound healing and
tumour growth [27–29]. FGF-2 has prominent roles in the repair and regeneration stages of
wound repair. In acute wound healing, FGF-2 promotes tissue repair by stimulating fibroblast
motility and collagenase production for extracellular matrix remodeling, promoting granula-
tion tissue formation, and increasing keratinocyte motility during re-epithelialization [30]. In
chronic wounds such as hypertrophic scars and keloids, the growth factor can attenuate fibrosis
and promote healing by down-regulating TGF-β induced collagen production, increasing
matrix degrading enzymes such as matrix metalloprotein-1 and inducing myofibroblast apo-
ptosis [31]. A role for FGF-2 in microfibril biology has yet to be documented.
We have found that FGF-2 has a single high-affinity binding site in a central region of
LTBP-2. In addition LTBP-2 inhibited FGF-2 induced fibroblast proliferation in a bioassay and
confocal microscopy showed strong co-localisation of LTBP-2 and FGF-2 in fibrotic keloid
skin.
Materials and Methods
Rabbit anti-[human LTBP-2 peptide] antibody 3504 has been described previously [17]. Anti-
His4 antibodies were purchased from Qiagen (Valencia, CA). FGF-2 antibody (#610871) for
LTBP-2 Interactions with FGF-2
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immunohistochemistry was supplied by BD labs. Recombinant human FGF-2, VEGF, BMP-4,
and BMP-7 and corresponding antibody detection systems (duo-set kits) were obtained from
R and D systems. Mouse anti-fibrillin-1 monoclonal antibody MAB1919 and rabbit anti-phos-
pho-FGFR1(Tyr653/Tyr654) antibody were obtained from Merck Millipore, Germany. Rabbit
monoclonal anti-total FGFR1 antibody (D8E4) was purchased from Cell Signalling Technol-
ogy (Danvers, MA).
Recombinant protein production and purification
CDNAs encoding recombinant human LTBP-2 and contiguous fragments NT(H), C(H) and
CT(H) were cloned into episomal expression vector pCEP4 as described previously [32]. In
addition, three contiguous sub-fragments of LTBP-2C(H), entitled F1, F2 and F3, were gener-
ated for the current study (Fig 1). Briefly, cDNAs encoding these sub-fragments were amplified
by PCR from the LTBP-2C (H) cDNA [32] and ligated into a modified episomal expression
vector BM40:his6:pCEP-4, such that each recombinant fragment was flanked by a BM-40
secretion-signal peptide and a C-terminal His6 tag. PCR amplification with Pfu turbo Cx DNA
polymerase (Stratagene) used 25 cycles of 95°C for 30 sec, annealing for 30 sec and extension
for 1 min at 72°C. For LTBP-2 C(H) F1, cDNA bases 775 to 1581 were amplified using sense
primer 50-CTGAAAGCTTGGACTCTCAGGCTGGCCAGG-30 and antisense primer 5’CACAA
AGCTTCACATCTTGGCAGCCCTTCTCAT- 3’, with an annealing temperature of 54°C, giving
a product of 807 bp. For LTBP-2 C(H) F2, cDNA bases 1553 to 2343 were amplified using
sense primer 5’- GAAGGGCTGCCAAAGCTTGGATGAGTGTGCCAG- 3’ and antisense primer
5’- CGTTAAGCTTCTCGTCTATGTCAATGCAG- 3’, with an annealing temperature of 62°C,
giving a product of 791bp. For LTBP-2 C(H) F3, cDNA bases 2315 to 3180 were amplified
using sense primer 5’-CTCCATTGAAAGCTTCGAGTGCGCCAACGACAC- 3’ and antisense
primer 50-TTTTAAGCTTGATGTCCATGTGGATGTCGT-30, with an annealing temperature of
54°C, giving a product of 866 bp. The PCR products were purified by excision from agarose
gels, A-tailed and ligated into the pGEM-T easy plasmid, as described previously [17]. The
ligated constructs were transformed into JM109 competent cells, and individual clones were
propagated and sequenced. Error-free cDNAs were then excised by digestion with HindIII,
and ligated into the HindIII site of the modified pCEP4 vector [17]. These expression con-
structs were transfected into 293-EBNA cells, and cells were grown with selection antibiotic
hygromycin B. The cell culture medium was harvested and recombinant protein was purified
using chelating Ni-Sepharose as previously described [33]. Samples of the recombinant pro-
teins were dialyzed into TBS-0.5M NaCl, and analyzed by SDS-PAGE on a 12% gel under both
reducing and non-reducing conditions to confirm size and purity.
Solid Phase Binding Assays
Solid phase binding assays were conducted as described previously [34] using an adaptation of
the method provided with the growth factor DuoSet ELISA Development kits (R&D Systems).
Briefly recombinant LTBP-2 or fragments was coated overnight onto microtitre wells, with
BSA-coated wells as negative controls. After washing, growth factor, usually FGF-2, was added
to the wells, at either a constant concentration, or in increasing amounts for the saturation
curve, and incubation was continued for 2 h. After thorough washing, bound growth factor
was detected by incubation for 2 h with biotinylated detection antibody (2.5 μg/ml) followed
by 20 min with streptavidin conjugated with horseradish peroxidase. Colour development
(absorbance at 450 nm) was detected using TMB substrate and quenched using 1M H2SO4. For
the FGF-2 saturation binding curves, the amount of FGF-2 bound was calculated from a con-
current standard ELISA for FGF-2, following the protocol provided in the DuoSet ELISA
LTBP-2 Interactions with FGF-2
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Development kit. The Kd for each interaction was calculated by non-linear regression analysis
of this saturation curve using GraphPad Prism (Version 4).
For heparin binding studies, binding assays were conducted with heparin-albumin conju-
gate [HAC] as described previously [32]. Briefly wells were coated overnight with HAC (or
BSA control) in TBS, followed by blocking with 5% milk-TBS for 1 hour. LTBP-2C (H) or frag-
ments F1, F2 and F3 were added to wells in TBS+2mM CaCl2, and incubated at 37°C for 3
hours. Following washing, primary antibody (usually anti-pentaHis) in TBS+2mM CaCl2 was
added to wells, and incubated at 37°C for 2.5 h. Binding was detected using goat anti[mouse
IgG] antibody-HRP conjugate followed by substrate development as described above.
Fig 1. Recombinant LTBP-2 Fragments. A. Schematic diagram of recombinant LTBP-2 fragments. Protein
fragments generated specifically for this study (LTBP-2C(H) F1, F2 and F3) are highlighted within the blue
box. FGF-2 binding was confined to a single central region of the LTBP-2 molecule consisting of 6 EGF-like
repeats (fragment LTBP-2C(H) F2).B. SDS-PAGE of purified recombinant LTBP-2 fragments. Samples of
purified fragments LTBP-2 C(H), LTBP-2 C(H) F1, LTBP-2 C(H) F2 and LTBP-2 C(H) F3 were analyzed on a
12% gel under non-reducing conditions and stained with Coomassie blue. The relative mobilities of protein
standards are indicated by arrows.
doi:10.1371/journal.pone.0135577.g001
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Cell proliferation assay
Human foreskin fibroblasts (passage 4) were suspended in DMEM plus 10% fetal calf serum,
non-essential amino acids, and penicillin/streptomycin. The cells were plated at a density of 4 x
104 cells per well into a 96-well culture plate (Costar #3596, Corning) and incubated overnight
at 37°C in a cell culture incubator (5% CO2). The wells were rinsed with serum-free DMEM
and further incubated at 37°C for 48 h in 100 μl of serum-free DMEM containing FGF-2 (10
ng/ ml, 0.625 nM). For some wells, the FGF-2 was pre-incubated for 15 min with five or ten
fold molar excess of LTBP-2 or fragment LTBP-2C F2 prior to addition of the mixture to the
wells. Follistatin (30 ng/well) was included in some incubations to ensure that observed effects
were not due to undetectable quantities of TGF-β in the recombinant LTBP-2 preparations
[35]. Cell proliferation was measured using metabolic substrate WST-1 (Roche) following the
manufacturer's instructions. Briefly 10 μl of WST-1 was added to each well. The plate was
rocked gently for 1 min to mix then returned to the cell culture incubator for 30 mins. A micro-
plate spectophotometer (Shimadzu UV-1601) was then used to read absorbances at 450 nm,
and 595 nm and the reading at 595 nm was subtracted from the 450 nm reading to give final
colour values.
Detection and quantitation of FGFR1 activation
Human foreskin fibroblasts were plated at a density of 4 x 105 cells per well into a 6-well plate
(Nunclon Surface, Nalge Nunc International, Denmark) and incubated overnight at 37°C in a
cell culture incubator (5% CO2) in DMEM plus 10% fetal calf serum. The wells were rinsed
with PBS and further incubated at 37°C for 2 hours with 1 ml of serum-free DMEM containing
FGF-2 (10ng/ml, 0.625 nM). For some wells, the FGF-2 was preincubated for 15 min with
10-fold molar excess of LTBP-2 or fragment LTBP-2C F2 prior to addition to the wells. The
cells were then lysed using extraction buffer (containing 50 mM Tris (pH 6.8), 0.5% SDS, 2
mM EDTA and cocktails of phosphatase and protease inhibitors [#04906837001 and
#11836153001, Roche, Germany]) and analysed by SDS-PAGE on 12% gels (100 ug cell protein
per well). The proteins were immunoblotted onto nitrocellulose membranes (0.2 μm, Pall Cor-
poration, Pensacola, FL) as described previously [34]. The membranes were blocked in a 5%
skim milk in TBS-Tween20 for 1 hr at RT with gentle shaking. The blots were horizontally cut
into 2 halves and incubated at 4°C overnight with 0.2ug/ml of anti-phospho-FGFR-1(Tyr653/
Tyr654) antibody (#06–1433, Millipore, CA) or anti-total FGFR1 antibody (#9740, CST, MA)
(upper half) or 1ug/ml of anti-β actin antibody (#SANTSC-47778, Santa Cruz Biotechnology,
Inc, USA) (lower half). After washing the blot halves with TBS-Tween, bands were visualised
with the appropriate anti-rabbit IgG or anti-mouse IgG antibodies conjugated with IR800 fluo-
rescence dye (#SA5-35571 or #SA5-35521, Thermo Scientific, U.S.A). Membranes were imaged
with the LI-COR Odyssey Infrared Imaging System. Bands were quantitated using ImageJ 1.48
software [National Institutes of Health (NIH), Bethesda, MD] and normalised to the internal
β-actin signal. For comparison of the phospho-FGFR1 signal between samples, the ratio of the
normalised phospho-FGFR1 signal to the total FGR1 signal was expressed as a percentage rela-
tive to the average value from cells treated with FGF-2 only (equaling 100%).
Immunohistochemistry
Paraffin-embedded tissue blocks of tissue from normal skin and keloid were prepared from
biopsy or discarded surgery material from adult human subjects with informed written consent
which is archived and human ethics clearances from the University of Adelaide (#H-16-2001)
and the Calvery Hospital Research Ethics Committee (11-CHREC-F007). Sections (4 μm thick-
ness) were cut via a microtome and dewaxed in xylene for 30 min and rehydrated gradually for
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2 min each through a series of ethanol solutions (100% to 30%) followed by water and finally
PBS. The slides were then placed in 15% target retrieval solution [36] for 60 mins, starting at
90°C and dropping to 65°C. The sections were washed in PBS, incubated with trypsin (0.025%
w/v) for 3 min at 37°C then blocked with 3% normal goat serum for 30 min. After washing
with PBS, the sections were incubated overnight at 4°C with primary antibodies (2 or 2.5 μg/
ml) or matched concentrations of appropriate rabbit or mouse IgG as negative controls. After
thorough washing in PBS, the sections were incubated for 1 h with a 1:200 dilution of appropri-
ate secondary antibody (anti-rabbit IgG antibody conjugated to fluor Alexa 488 or anti-mouse
IgG antibody conjugated to Alexa 594, Life Technologies). After further washing with PBS the
sections were treated with 0.1μg / ml of 40,6-Diamidino-2-phenylindole dihydrochloride
(DAPI) [Sigma; D9542] and sealed under a coverslip in Dako fluorescence mounting medium.
The slides were examined using a Leica TCS SP5 confocal microscope, sequentially excited at
488 nm for Alexa 488 (emission window 496–533 nm), 561 nm for Alexa 594 (emission win-
dow 569–753 nm) and 405 nm for DAPI (emission window 413–460 nm). For quantitation, 3
random areas (each 0.038 mm2) per section were analysed using the AnalySIS software package
(Soft-Imaging System, Munster, Germany).
Results and Discussion
FGF-2 has a strong affinity for LTBP-2
Expression constructs in a modified pCEP4 vector for full-length human LTBP-2 and three
contiguous fragments spanning the molecule have been described previously [32]. In addition
similar constructs encoding three smaller recombinant fragments spanning the central region
of the LTBP-2 molecule were made, each encoding an N-terminal BM40 signal peptide and a
C-terminal His6 tag (Fig 1A). Each encoded fragment was produced in 293-EBNA cells and
purified from the culture medium as previously described [32]. Each protein fragment gave a
single band on SDS-PAGE (Fig 1B) indicating a high degree of purity. Fragments LTBP-2C F1,
F2 and F3 (predicted molecule weights of 29 kDa, 28 kDa and 31 kDa respectively) migrated
under non-reducing conditions with apparent molecular weights of 40 kDa, 30 kDa and 37
kDa respectively.
Full-length recombinant LTBP-2 was tested for binding to a range of growth factors includ-
ing vascular endothelial growth factor, BMP-4, BMP-7 and FGF-2 in an established solid phase
binding assay (Fig 2A) [34]. Initial screening identified FGF-2 and BMP-4 as candidate binding
partners for LTBP-2. However a further experiment identified BMP-4 as a false positive, as the
BMP-4 antibody showed binding to the LTBP-2 coated wells in the absence of BMP-4 protein
(Fig 2B). Of the growth factors tested only FGF-2 showed strong saturable binding to LTBP-2
(Fig 3A). The binding curve was quantitated from a standard ELISA curve for FGF-2 coated
onto microtitre wells. This enabled the Kd for the LTBP-2 / FGF-2 interaction to be calculated
by non-linear regression analysis of the curve produced by plotting amount FGF-2 bound ver-
sus concentration of FGF-2 added (Fig 3B). The prism program calculated the Kd as
1.11 ± 0.17 nM for a single binding site. This finding indicated that the LTBP-2 / FGF-2 inter-
action is of high affinity.
FGF-2 binding is confined to a small central region of the LTBP-2
molecule
To identify the FGF-2 binding region(s) on LTBP-2, a range of recombinant LTBP-2 fragments
were tested in the FGF-2 binding assay (Fig 4). Initially the three large fragments spanning the
LTBP-2 molecule were tested with central fragment LTBP-2C(H) alone showing strong FGF-2
LTBP-2 Interactions with FGF-2
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Fig 2. LTBP-2 specifically binds FGF-2 but not VEGF, BMP-4, BMP-7 or TGF-beta. A. Microtitre wells were coated with rLTBP-2 (black columns) or BSA
(shaded columns) (100 ng/ well). After blocking, triplicate wells were incubated at 37°C for 2h with TGF-beta (13 ng / well), VEGF (21 ng / well), BMP-7 (4 ng/
well), BMP-4 (4 ng / well) or FGF-2 (10 ng / well). Growth factor binding was detected using specific biotinylated antibodies from Duoset kits as described in
material and methods. Mean values ± S.D. from triplicate wells are shown.B. Microtitre wells were coated with rLTBP-2 (100ng/well) was coated onto
microtitre plates. After blocking, triplicate wells were incubated at 37°C for 2h with (black columns) or without (cross-hatched) growth factor, (BMP-4 (4ng/
well) or FGF-2 (10ng/well). Binding of growth factor to LTBP-2 was detected using biotinylated anti-BMP-4 detection antibody (0.5ug/ml) or anti-FGF-2
detection antibody (0.25ug/ml), followed by a peroxidase detection method (see material and methods). Mean values ± S.D. from triplicate wells are shown.
Note the anti-BMP-4 antibody bound to the wells equally strongly in the presence or absence of added BMP-4, indicating the interaction was non-specific.
doi:10.1371/journal.pone.0135577.g002
Fig 3. LTBP-2 interacts strongly with FGF-2. A. Microtitre wells were coated with 200 ng rLTBP-2 or BSA control. After blocking, triplicate wells were
incubated with 0–1.8 nM concentrations of FGF-2 (0–30 ng/ml) for 3 h at 37°C. FGF-2 binding was detected following sequential incubation of the wells with
biotinylated mouse anti-[human FGF-2] antibody and streptavidin-HRP conjugate following the duoset protocol. Circles, LTBP-2; squares, BSA. Mean
values ± S.D. of triplicate determinations are shown.B. Kd calculation. Following subtraction of the average BSA signal, the A450nm values were converted
to fmol of FGF-2 using a standard ELISA curve (not shown). An additional graph was plotted of bound versus added FGF-2 and the Kd for interaction with
LTBP-2 was calculated by non-linear regression analysis of the curve using the prism 4.0 program. Mean values ± S.D. from triplicate determinations are
shown.
doi:10.1371/journal.pone.0135577.g003
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Fig 4. FGF-2 has a single binding domain in the central region of LTBP-2. A. Three recombinant
fragments spanning the LTBP-2 molecule were tested for binding to FGF-2 in a solid phase assay. Full length
LTBP-2(H), fragments LTBP-2 NT (H), LTBP-2C (H), LTBP-2 CT (H) or BSA control were coated onto wells
at 100 ng/ml, followed by incubation with FGF-2 (100ng/ml) for 3h at 37°C. Strong specific binding to central
fragment LTBP-2C(H) was detected as described in Fig 2A. Mean values ± S.D. from triplicate wells are
shown.B. A binding curve was produced for the FGF-2 interaction with fragment LTBP-2C(H) following the
LTBP-2 Interactions with FGF-2
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binding (Fig 4A). Subsequently three sub-fragments F1, F2, and F3 spanning LTBP-2C(H)
were produced and tested with only the F2 showing strong FGF-2 binding (Fig 4C). This indi-
cated that FGF-2 binding activity was confined to a small central region of LTBP-2 consisting
of 6 calcium binding EGF-like repeat motifs (motifs 9–14) (see Fig 1A). Binding curves for
fragment LTBP-2C(H) (not shown) and sub-fragment F2 (Fig 4D) were produced and the Kds
for FGF-2 binding were calculated as previously for full length LTBP-2. The Kds for FGF-2
interaction with LTBP-2C(H) and F2 were calculated as 1.02 ± 0.19 nM (Fig 4B) and
1.03 ± 0.10 nM (Fig 4E) respectively indicating similar affinities for FGF-2 as the full-length
LTBP-2 molecule. The binding affinity of LTBP-2 for FGF-2 was similar to that we reported
for heparin [32] but was significantly higher than LTBP-2 interactions with fibrillin-1 (9 nM)
and fibulin-5 (26 nM) using the same methodology [16, 17]. In an attempt to identify the pre-
cise binding site for FGF-2 on LTBP-2 we produced 6 peptides corresponding to each EGF-like
motif of the FGF-2 binding region. However no direct FGF-2 binding or inhibition of the
LTBP-2-FGF-2 interaction was identified for any of the peptides (data not shown). This indi-
cates that the binding site may span two or more EGF-like repeats.
The FGF-2 binding site is close to a heparin-binding region of LTBP-2
We have previously identified several heparin-binding regions on LTBP-2 including a central
site of moderate affinity contained in fragment LTBP-2C(H) [32]. Since FGF-2 also has affinity
for heparin/heparan sulphate we determined if the FGF-2 and heparin binding sites were con-
tained in the same or distinct sub-fragments of LTBP-2C(H). Using the solid phase binding
assay, fragments LTBP-2C(H) and sub-fragment F2 showed strong binding to heparin-albu-
min conjugate coated wells, whereas sub-fragments showed no binding above the control wells
coated with BSA (Fig 5). Thus both the central heparin binding region and the FGF-2 binding
site on LTBP-2 are present within six EGF-like repeats of each other. This site was reported to
have moderate affinity for heparin with a Kd estimated at 80 nM compared to a cluster of
higher affinity sites identified in the N-terminal region of LTBP-2 [32].
LTBP-2 blocks FGF-2-induced cell proliferation
To determine if LTBP-2 enhanced or inhibited FGF-2 bioactivity a cell proliferation assay was
conducted (Fig 6A). Addition of exogenous FGF-2 was found to significantly increase the rate
of proliferation of fibroblasts in serum-free culture over 48 h, to a similar extent in the presence
or absence of activin/TGF-β inhibitor follistatin. However pre-incubation of the FGF-2 with
full-length LTBP-2 in 5-fold or 10-fold molar excess prevented any FGF-2-induced cell prolif-
eration. Pre-incubation with fragment LTBP-2C-F2, which contains the FGF-2 binding site,
protocol described under Fig 2, with 400 ng/well (4.8 pmol) of LTBP-2C (H) or BSA control coated on the
wells incubated with increasing concentrations FGF-2 (0–1.5 nM). The Kd for binding of FGF-2 to fragment
LTBP-2C (H) was calculated as 1.02 ± 0.19 nM. Mean values ± S.D. from triplicate determinations are shown.
C. Three sub-fragments F1, F2 and F3 spanning fragment LTBP-2 C(H) were produced and tested for FGF-2
binding as described under Fig 2. LTBP-2C (H) (200 ng/well, 2.4 pmol) or sub-fragment (F1, F2 or F3) (66ng/
well, 2.4 pmol) or BSA control was coated on the wells and incubated with FGF-2 (100 ng/ml). Strong specific
binding of FGF-2 to sub-fragment LTBP-2C F2 was detected. Mean values ± S.D. from triplicate wells are
shown.D. Subsequently binding curves were obtained for sub-fragments F1 (solid squares), F2 (open
circles), F3 (solid circles) (35 ng/well, 1.2 pmol) coated on the wells and incubated with increasing
concentrations of FGF-2 (0–30 ng / ml). Note specific FGF-2 binding to sub-fragment LTBP-2C F2 but no
binding of fragments F1 and F3 above the BSA control (triangles). Mean values ± S.D. from triplicate
determinations are shown. E. The Kd for the FGF-2 interaction with sub-fragment LTBP-2C F2 was
calculated as 1.03 ± 0.10 nM which is similar to the Kds calculated for the interactions of FGF-2 with full-
length LTBP-2 and fragment LTBP2C. Mean values ± S.D. from triplicate determinations are shown.
doi:10.1371/journal.pone.0135577.g004
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also significantly inhibited, but did not completely block, FGF-2 induced cell proliferation.
Controls conducted in the absence of FGF-2 showed that follistatin, LTBP-2 or fragment
LTBP-2C F2 had no significant effect on cell proliferation. To determine if LTBP-2 blocked the
activation of the FGF receptor, the experiment was repeated and cellular proteins were
extracted after 2 hours and analysed by SDS-PAGE and immunoblotting (Fig 6B and 6C). The
results clearly showed that the control cells had no detectable activated FGFR1 but the addition
of FGF-2 resulted in a strong FGFR1 signal. Additional of excess full length LTBP-2 completely
blocked the activation of the receptor but the same molarity of fragment LTBP-2CF2 greatly
reduced but did not completely prevent FGFR1 activation. Overall the experiment indicated
that LTBP-2 inhibits rather than enhances FGF-2 activity. It is noteworthy that the 6-EGF-like
repeat fragment containing the FGF-2 binding sequence (LTBP-2C F2) only partially inhibited
the mitogenic effect of FGF-2. Thus additional sequences adjacent to fragment F2 may be
important for the full influence of LTBP-2 on FGF-2 bioactivity.
LTBP-2 and FGF-2 show similar distributions in fibrotic skin
To determine if the interaction of LTBP-2 and FGF-2 could have biological relevance we
searched for overlapping of immunofluorescence localization patterns in normal and fibrotic
skin. Neither protein showed discernible localization within the extracellular matrix of normal
Fig 5. The FGF-2 binding site is close to the central heparin binding site on LTBP-2. In a previous study
[32] we identified LTBP-2 C(H) as a heparin-binding fragment of LTBP-2. To further define the location of this
heparin binding activity, the three sub-fragments F1, F2, F3 spanning LTBP-2 C(H), were assayed for heparin
binding using a heparin-albumin conjugate (HAC). HAC or BSA control (400 ng) was coated on wells followed
by incubation with equimolar concentrations (23.5 nM) of LTBP-2C(H) or sub-fragment F1, F2 or F3. Specific
binding was detected using anti-His4 antibody targeting the poly-His tag on each recombinant fragment.
Fragment F2 showed strong specific binding to the heparin conjugate in contrast to F1 and F3 which showed
no binding above background. Mean values ± S.D. from triplicate wells are shown.
doi:10.1371/journal.pone.0135577.g005
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adult skin (data not shown). LTBP-2 gene mutations have been linked to WMS which demon-
strates thickened fibrotic skin suggesting a connection between LTBP-2 and fibrosis [18]. We
therefore examined LTBP-2 expression in fibrotic keloid tissue that has elevated production of
new elastic fibres [37, 38]. Keloids are fibrotic scars that are raised above skin level and project
beyond the original wound margins [39]. The keloid tissue stained very strongly for LTBP-2
with a widespread, fibrous distribution (Fig 7A) which closely matched the distribution of
fibrillin-1 (Fig 7B) as confirmed by the merged images (Fig 7C). Control sections incubated
with rabbit or mouse IgG in place of antibody showed no discernible staining (Fig 7D and 7E).
At high power, fine irregular fibres staining for both LTBP-2 (Fig 7F) and fibrillin-1 (Fig 7G)
were evident in the intercellular matrix, visualized as yellow staining in the merged image (Fig
7H). The results indicate that LTBP-2 is predominantly associated with fibrillin-containing
Fig 6. LTBP-2 blocks FGF-2-induced cell proliferation. A. The effect of LTBP-2 on the bio-activity of FGF-2 was tested in a cell proliferation assay (see
experimental). Human foreskin fibroblasts were treated with FGF-2 with and without follistatin (white columns), or FGF-2 and follistatin pre-incubated with 5 or
10 fold molar excess of full length LTBP-2 or fragment LTBP-2C F2 (cross-hatched). Negative controls (black columns), included cells only and cells
incubated with follistatin, LTBP-2 or fragment LTBP-2C F2. Mean values ± S.D. from triplicate determinations. Note 5 fold molar excess of full-length LTBP-2
completely blocked FGF-2 induced cell proliferation (p = 0.0001) and 5-fold molar excess of fragment LTBP-2C F2 partially blocked the activity (p = 0.0001).
B. Immunoblot analysis FGF receptor (FGFR1) phosphorylation. Human foreskin fibroblasts were treated for 2 hours with FGF-2 (10 ng / ml) only or with
FGF-2 plus 10-fold molar excess of full length LTBP-2 (LTBP-2 FL) or fragment F2 (LTBP-2C F2). Control cells had no FGF-2 or LTBP-2 added. Cellular
proteins were extracted and duplicate samples were analysed by SDS-PAGE and immunoblotting with anti-phospho-FGFR1 antibody, and anti-total FGFR1
antibody. Bands were visualised using the LI-COROdyssey Infrared Imaging System.C. The band intensity was measured using ImageJ 1.48 software
[National Institutes of Health (NIH), Bethesda, MD] and normalised to the internal β actin signal. The ratio of the phospho-FGFR1 to total FGFR1 value for
each sample is expressed relative to the average FGF-2 only control value (= 100%). Note the strong FGFR1 activation by FGF-2 was substantially blocked
by both LTBP-2 C and LTBP-2C F2 fragments. Mean values ± S.D. of duplicate lanes.
doi:10.1371/journal.pone.0135577.g006
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microfibrils, which are components of elastic fibres. These findings are consistent with previ-
ous studies showing strong co-localization of LTBP-2 and developing elastin fibres in fetal tis-
sues and in tissue remodelling [8, 10, 40]. The elastic fibres generally ran parallel to the
epithelium although some areas showed a more random distribution consistent with previous
reports [37, 38]. Interestingly a similar intense immuno-staining pattern was found for FGF-2
in sections of fibrotic keloid skin from several patients. An example from one patient is shown
in Fig 7. Low power images show intense discrete staining for LTBP-2 (Fig 8A-green) and
FGF-2 (Fig 8B-red) to the same structures throughout the keloid as confirmed from the merged
image (Fig 8C) where co-localization is visualized as yellow-orange. At higher power, LTBP-2
(Fig 8F-green) and FGF-2 (Fig 8G-red) antibodies stained the same fibres within the extracellu-
lar matrix as well as cellular elements (identified using the blue nuclear DAPI stain). The exten-
sive overlap of staining for the two proteins is confirmed by the merged image (Fig 8H) where
the co-localization is visualized as yellow staining. The appropriate immunoglobulin controls
showed little background staining (Fig 8D and 8E). As an additional control a section was
stained for LTBP-2 and VEGF which has no known affinity for fibrillin microfibrils (Fig 8I).
No overlap in the distributions were observed, with VEGF detected only in association with
some but not all of the stromal cells and showing no localization within the extracellular
matrix. The close proximity of FGF-2 to LTBP-2 within the keloid indicates that the two pro-
teins may directly interact in the matrix of fibrotic skin on the surface of newly generated elas-
tic fibres where they may influence, in vivo, the biological activity of each other. The
significance of the strong intracellular staining for both proteins is less clear. It seems likely
that this simply reflects high synthesis rates for both proteins in fibrotic tissues although a
direct intracellular interaction cannot be ruled out. Quantitation of the relative immunofluo-
rescence signals between normal skin and keloid showed around 9-fold increases in signals for
Fig 7. LTBP-2 and fibrillin-1 colocalize in fibrotic skin. Keloid tissue was prepared and analyzed by confocal microscopy as described in the methods
section.A and F, polyclonal anti-[human LTBP-2 peptide] antibody 3504 (2 μg/ ml) detected with anti-rabbit IgG antibody conjugated to fluor Alexa 488;B
and G, monoclonal anti-[fibrillin-1] antibody MAB1919 (Merck millipore) (2.5 μg/ml) detected with anti-mouse IgG antibody conjugated to Alexa 594;C, A and
B merged;D, rabbit IgG control (2 μg/ ml); E, mouse IgG control (2.5 μg / ml); H, F, G and I merged; I, DAPI nuclear stain. Magnification: top row,
Bar = 100 μm; bottom row, Bar = 10 μm.
doi:10.1371/journal.pone.0135577.g007
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both LTBP-2 and FGF-2 in the keloid tissue suggesting that production of both proteins was
greatly increased in the fibrotic condition (Fig 9).
Our results have shown that LTBP-2 strongly binds and inactivates FGF-2 in vitro and that
both proteins appear to co-localize with fibrillin-microfibrils in fibrotic tissues. However the
importance of these observations in microfibril and elastic fibre biology, and pathophysiology
of relevant congenital and fibrotic diseases, remains to be established. The paradigm of the
congenital disease MFS and related disorders has demonstrated that fibrillin microfibrils are
important for growth factor regulation. Mutations in fibrillin genes cause a reduction in the
number of normal microfibrils in tissues, resulting in inappropriate or excessive activation of
latent TGF-β during tissue development and growth [7, 20]. This aberrant TGF-β signaling is
considered to be a major contributor to the malformation and dysfunction of the cardiovascu-
lar, skeletal, pulmonary and ocular systems characteristic of MFS. The mechanism of this TGF-
β activation appears to be more complex than originally envisaged. Isogai et al showed that
LTBP-1, 3 and 4 share a single binding site on fibrillin-1 and suggested that disruption of this
binding activity would reduce matrix storage of the LTBP-TGF-β latent complexes resulting in
excessive growth factor activation [41]. However subsequent research with mutant mice
showed that total deletion of this binding site on fibrillin-1 caused no obvious disease pheno-
type [42]. More recently Zilberberg et al demonstrated that LTBP-1, the major contributor to
latent TGF-β sequestration, required only fibronectin and not fibrillin 1 or 2 for matrix attach-
ment [43]. The findings suggest that other mechanisms in addition to direct liberation of latent
TGF-β from the fibrillin microfibrils may contribute to elevation of the TGF-β signalling. Since
fibrillin and associated proteins also bind a range of other potent cytokines, it seems likely that
disruption of normal microfibrils will activate other signalling pathways perhaps leading to
indirect TGF-β elevation. It appears that LTBP-2 requires fibrillin-1 microfibrils for
Fig 8. LTBP-2 and FGF-2 co-localize in keloid tissue. Keloid tissue was also analyzed for LTBP-2 and FGF-2 by confocal microscopy. A and F, polyclonal
anti-[human LTBP-2 peptide] antibody 3504 (2 μg/ ml) detected with anti-rabbit IgG antibody conjugated to fluor Alexa 488;B and G, monoclonal anti-[human
FGF-2] antibody #61087 (BD Biosciences) (2.5 μg/ml) detected with anti-mouse IgG antibody conjugated to Alexa 594; C, A and Bmerged;D, rabbit IgG
control (2 μg/ ml); E, mouse IgG control (2.5 μg / ml); H, F, and Gmerged; I, Control confocal image showing distinct immunostaining patterns for VEGF (red)
and LTBP-2 (green). Magnification: top row, Bar = 100 μm; bottom row, Bar = 50 μm.
doi:10.1371/journal.pone.0135577.g008
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incorporation into the extracellular matrix [44] and thus loss of these structures is likely to dis-
rupt matrix sequestration of LTBP-2 and any attached proteins such as FGF-2. Depending on
context FGF-2 can stimulate TGF-ß gene expression [45] and secretion [46] or can inhibit
TGF-β induced fibrosis [31]. Thus it is difficult to predict possible effects of disrupting LTBP-
2/FGF-2 interactions in WMS and other relevant diseases. The LTBP-2 gene has also been
linked to tumor suppression in squamous cell carcinoma and meningioma, [47, 48] and as a
marker for pulmonary deaths following acute dyspnea [49]
It also remains to be established how LTBP-2 relates to FGF-2 functional biology. FGF-2
lacks a secretion signal [50] and is secreted from cells by an unknown mechanism and becomes
strongly bound to the GAG side-chains of HSPGs in the matrix and basement membranes [51,
52] Following tissue injury, the FGF- 2 molecules are released by protease and heparinase activ-
ity. Multiple FGF-2 molecules remain attached to released HS chains and subsequent interac-
tion with cell surface FGF-receptors causes clustering of the FGFR molecules necessary to
activate intracellular signaling pathways [51, 52]. FGF-2 achieves its diverse effects by
Fig 9. Quantitation of LTBP-2 and FGF-2 in normal skin and keloid. The relative fluorescence intensities
of LTBP-2 and FGF-2 staining (and appropriate IgG controls) in sections of normal human skin (black
columns) and keloid (shaded columns) was quantitated from 3 random areas (each 0.038 mm2) per section
using the AnalySIS software package (Soft-Imaging System, Munster, Germany). Values expressed relative
to the background control signal (= 1 unit). Mean values ± S.D. of triplicate determination are shown.
doi:10.1371/journal.pone.0135577.g009
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stimulating several major cell signaling pathways including RAS/MAPK, PI3K/AKT and PLC-
U [53] and in complex with cell surface heparan sulphate proteoglycans, the ERK1/2 pathway
[54].
We have shown here that the FGF-2 binding site of LTBP-2 is adjacent to a heparin binding
site of moderate affinity. LTBP-2 also has multiple high affinity binding sites for heparin/
heparan sulfate in its N-terminal region, binds HSPGs perlecan in vitro [32] and partially co-
localizes with the proteoglycan in some tissues [55, 56]. The findings suggest that LTBP-2, in
addition to free FGF-2, may also target and inhibit heparan sulphate-bound growth factor.
Interestingly, Cain et al. have recently shown that fibrillin-1 interactions with heparan sulfate
may be disrupted in WMS [57] and it is possible that LTBP-2 interactions with FGF-2 and
heparan sulfate are affected in WMS cases linked to LTBP-2 gene mutations.
The association of LTBP-2 with elastic fibres is well documented during periods of active
elastinogenesis [8, 40] but the protein is not ubiquitously associated with all elastic fibres [17].
This restriction may explain why FGF-2 localization to elastic fibres has not previously been
reported since its association may be dependent on the presence of LTBP-2. The high levels of
LTBP-2 in keloid tissue suggests a potential role for the protein in fibrosis. FGF-2 has an anti-
fibrotic role in the later stages of wound healing and exogenous FGF-2 has been used to effect
in treatment of hypertrophic scar and keloid tissues [31, 58]. An intriguing possibility is that in
keloid and perhaps other fibrotic disorders elevated LTBP-2 may bind and inactivate FGF-2,
inhibiting its contribution to resolution and healing of the condition and perpetuating the
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